|Dr. David Lionel Brookes FACRRM, FAICD, MBBS||Exec. Chairman||118.82k||N/A||1960|
|Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.||Chief Operations Officer||N/A||N/A||N/A|
|Jane Lowe||Managing Director of IR Department||N/A||N/A||N/A|
|Mr. Simon Erskine||Chief Devel. Officer||N/A||N/A||N/A|
|Dr. Stephen Denaro AGIA, BCom, GradDipApp CG, CA, MAICD||Company Sec.||N/A||N/A||N/A|
|Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management||Commercial Mang.||N/A||N/A||N/A|
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Anatara Lifesciences Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.